Related Experiment Video
Updated: Dec 6, 2025
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
The Impact of COVID-19 Disease on Platelets and Coagulation
Geoffrey D Wool1, Jonathan L Miller2
1Department of Pathology, University of Chicago, Chicago, Illinois, USA, Geoffrey.Wool@uchospitals.edu.
Insights
Coronavirus disease 2019 (COVID-19) causes severe inflammation and unique blood clotting issues, increasing mortality risk. While hypercoagulability and thrombosis are common, severe bleeding and DIC are rare in COVID-19 patients.
Area of Science:
- Hematology
- Infectious Diseases
- Critical Care Medicine
Background:
- Coronavirus disease 2019 (COVID-19) presents with a wide range of clinical manifestations.
- A subset of patients develops severe systemic inflammation, characterized by a procoagulant endothelial phenotype and coagulopathy.
- Understanding the hemostatic alterations in COVID-19 is crucial for patient management.
Purpose of the Study:
- To review the current understanding of hemostasis and thrombosis in COVID-19.
- To summarize the key hemostatic abnormalities observed in COVID-19 patients.
- To discuss the implications of these findings for clinical outcomes.
Main Methods:
- Literature review of studies investigating hemostasis in COVID-19.
- Analysis of laboratory markers of coagulation and platelet function.
- Examination of clinical data regarding thrombotic and bleeding events.
Main Results:
- COVID-19 is associated with elevated fibrinogen and D-dimer levels, indicating hypercoagulability.
- Increased risk of venous and arterial thromboembolic events, including strokes and pulmonary vascular microthrombosis.
- Mild thrombocytopenia with increased platelet turnover is common; disseminated intravascular coagulopathy and severe bleeding are infrequent.
Conclusions:
- COVID-19 significantly impacts hemostasis, leading to a prothrombotic state.
- Elevated D-dimer levels correlate with COVID-19 patient mortality.
- While thrombotic complications are prevalent, severe bleeding is uncommon, distinguishing COVID-19 coagulopathy from typical DIC.
Abstract:
Coronavirus disease 2019 (COVID-19) causes a spectrum of disease; some patients develop a severe proinflammatory state which can be associated with a unique coagulopathy and procoagulant endothelial phenotype. Initially, COVID-19 infection produces a prominent elevation of fibrinogen and D-dimer/fibrin(ogen) degradation products. This is associated with systemic hypercoagulability and frequent venous thromboembolic events. The degree of D-dimer elevation positively correlates with mortality in COVID-19 patients. COVID-19 also leads to arterial thrombotic events (including strokes and ischemic limbs) as well as microvascular thrombotic disorders (as frequently documented at autopsy in the pulmonary vascular beds). COVID-19 patients often have mild thrombocytopenia and appear to have increased platelet consumption, together with a corresponding increase in platelet production. Disseminated intravascular coagulopathy (DIC) and severe bleeding events are uncommon in COVID-19 patients. Here, we review the current state of knowledge of COVID-19 and hemostasis.
Related Concept Videos
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:09Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...